Antiphospholipid syndrome: a clinical review

Veronica Mezhov, Julian D. Segan, Huyen Tran, Flavia M. Cicuttini

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Antiphospholipid syndrome is characterised by recurrent thrombosis (arterial, venous, microvascular) and/or pregnancy complications in the presence of persistent antiphospholipid antibodies (lupus anticoagulant, anti-β2-glycoprotein 1 and anticardiolipin). It can be a primary disease or associated with another autoimmune disease (especially systemic lupus erythematosis). Testing for antiphospholipid antibodies should be considered in patients < 50 years of age with unprovoked venous or arterial thromboembolism, thrombosis at unusual sites or pregnancy complications. The mainstay of treatment is antithrombotic therapy and recommendations vary based on arterial, venous or pregnancy complications. If associated with systemic lupus erythematosis, hydroxychloroquine is recommended both as primary and secondary prophylaxis. Antithrombotic treatment is gold standard and effective.

Original languageEnglish
Pages (from-to)184-188
Number of pages5
JournalMedical Journal of Australia
Volume211
Issue number4
DOIs
Publication statusPublished - Aug 2019

Keywords

  • Anticoagulants
  • Autoimmune diseases
  • Lupus erythematosus, systemic
  • Review article
  • Thromboembolism

Cite this

Mezhov, Veronica ; Segan, Julian D. ; Tran, Huyen ; Cicuttini, Flavia M. / Antiphospholipid syndrome : a clinical review. In: Medical Journal of Australia. 2019 ; Vol. 211, No. 4. pp. 184-188.
@article{8d24a93843354cd1a1cef7329377520c,
title = "Antiphospholipid syndrome: a clinical review",
abstract = "Antiphospholipid syndrome is characterised by recurrent thrombosis (arterial, venous, microvascular) and/or pregnancy complications in the presence of persistent antiphospholipid antibodies (lupus anticoagulant, anti-β2-glycoprotein 1 and anticardiolipin). It can be a primary disease or associated with another autoimmune disease (especially systemic lupus erythematosis). Testing for antiphospholipid antibodies should be considered in patients < 50 years of age with unprovoked venous or arterial thromboembolism, thrombosis at unusual sites or pregnancy complications. The mainstay of treatment is antithrombotic therapy and recommendations vary based on arterial, venous or pregnancy complications. If associated with systemic lupus erythematosis, hydroxychloroquine is recommended both as primary and secondary prophylaxis. Antithrombotic treatment is gold standard and effective.",
keywords = "Anticoagulants, Autoimmune diseases, Lupus erythematosus, systemic, Review article, Thromboembolism",
author = "Veronica Mezhov and Segan, {Julian D.} and Huyen Tran and Cicuttini, {Flavia M.}",
year = "2019",
month = "8",
doi = "10.5694/mja2.50262",
language = "English",
volume = "211",
pages = "184--188",
journal = "Medical Journal of Australia",
issn = "0025-729X",
publisher = "AMPCo",
number = "4",

}

Antiphospholipid syndrome : a clinical review. / Mezhov, Veronica; Segan, Julian D.; Tran, Huyen; Cicuttini, Flavia M.

In: Medical Journal of Australia, Vol. 211, No. 4, 08.2019, p. 184-188.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Antiphospholipid syndrome

T2 - a clinical review

AU - Mezhov, Veronica

AU - Segan, Julian D.

AU - Tran, Huyen

AU - Cicuttini, Flavia M.

PY - 2019/8

Y1 - 2019/8

N2 - Antiphospholipid syndrome is characterised by recurrent thrombosis (arterial, venous, microvascular) and/or pregnancy complications in the presence of persistent antiphospholipid antibodies (lupus anticoagulant, anti-β2-glycoprotein 1 and anticardiolipin). It can be a primary disease or associated with another autoimmune disease (especially systemic lupus erythematosis). Testing for antiphospholipid antibodies should be considered in patients < 50 years of age with unprovoked venous or arterial thromboembolism, thrombosis at unusual sites or pregnancy complications. The mainstay of treatment is antithrombotic therapy and recommendations vary based on arterial, venous or pregnancy complications. If associated with systemic lupus erythematosis, hydroxychloroquine is recommended both as primary and secondary prophylaxis. Antithrombotic treatment is gold standard and effective.

AB - Antiphospholipid syndrome is characterised by recurrent thrombosis (arterial, venous, microvascular) and/or pregnancy complications in the presence of persistent antiphospholipid antibodies (lupus anticoagulant, anti-β2-glycoprotein 1 and anticardiolipin). It can be a primary disease or associated with another autoimmune disease (especially systemic lupus erythematosis). Testing for antiphospholipid antibodies should be considered in patients < 50 years of age with unprovoked venous or arterial thromboembolism, thrombosis at unusual sites or pregnancy complications. The mainstay of treatment is antithrombotic therapy and recommendations vary based on arterial, venous or pregnancy complications. If associated with systemic lupus erythematosis, hydroxychloroquine is recommended both as primary and secondary prophylaxis. Antithrombotic treatment is gold standard and effective.

KW - Anticoagulants

KW - Autoimmune diseases

KW - Lupus erythematosus, systemic

KW - Review article

KW - Thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=85068516186&partnerID=8YFLogxK

U2 - 10.5694/mja2.50262

DO - 10.5694/mja2.50262

M3 - Review Article

C2 - 31271468

AN - SCOPUS:85068516186

VL - 211

SP - 184

EP - 188

JO - Medical Journal of Australia

JF - Medical Journal of Australia

SN - 0025-729X

IS - 4

ER -